CA2067475C — Carbostyril derivatives and their use
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2000-10-10 · 26y expired
What this patent protects
Disclosed are carbostyril derivatives of the general formula (see above formula) wherein R1a is a halogen or a lower alkoxy, lower alkyl, lower alkenyloxy, amino, lower alkanoylamino or lower alkylthio group; R2 is a phenyl group which optionally may have one or two substitu…
USPTO Abstract
Disclosed are carbostyril derivatives of the general formula (see above formula) wherein R1a is a halogen or a lower alkoxy, lower alkyl, lower alkenyloxy, amino, lower alkanoylamino or lower alkylthio group; R2 is a phenyl group which optionally may have one or two substituents each independently selected from the group consisting of halogen, lower alkoxy, lower alkyl, nitro, amino, lower alkanoylamino, hydroxyl, cyano, phenyl-lower alkoxy and halo-lower alkyl; A is a lower alkylene group; and the carbon-carbon bond between the positions 3 and 4 of the carbostyril skeleton is a single bond or a double bond; and salts thereof, and pharmaceutical compositions containing the same, for use as a disturbance-of-consciousness improving agent, central nervous system stimulent or sigma receptor agonist.
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.